The landscape of cancer treatment has continued to evolve, and the annual ASCO Meetings often set the stage for “what’s next in cancer care.” The overarching narrative at the 2024 ASCO Annual Meeting “From Comfort to Cure,” calls providers to view treatment plans with an emphasis on quality of life. To answer this call, we must implement solutions that enable providers to maintain the quality of life without compromising the quality of care.
Quality of life is personal
Providers desire to personalize their patient’s care. It is important to engage in shared decision-making with patients to understand what quality of life means for them and how a specific treatment could impact their lifestyle; these factors include a patient’s physical, mental, and financial well-being. The primary focus of most cancer treatments is to eradicate the disease, however, this can come at the expense of the patient’s comfort around the aforementioned factors.
Chemotherapy, known for its role in cancer care, is effective but it comes at a cost – both physically and mentally. However, the latest advancements and discussions at ASCO 2024 indicate a trend that providers are asking “Is chemo necessary?”
Another staple in cancer treatment is surgery to remove cancerous tissue and surrounding healthy tissue to prevent recurrence. Surgery is a leading method to remove skin cancer – the most common cancer in the United States. There are cases, however, when surgery may not be possible or the best choice. For example, skin cancer often occurs on the face due to sun exposure, and surgery in certain facial regions could lead to disfigurement or even the removal of entire facial areas. These considerations highlight the need for alternative approaches that balance efficacy with the preservation of the patient’s quality of life.
While these are just two examples, there are several treatment options and combinations where a provider can pause and assess if the physical toll e.g., toxicity, or emotional toll, e.g., disfigurement is required.
Quantity of years should not diminish the quality of life when determining cancer treatment
Recently, the World Health Organization shared a prediction that cancer cases will rise by 77% by 2050. This is partly due to an aging population, with people living longer in the United States than ever before. With increased age can come increased complications when selecting a cancer treatment. For example, in skin cancer, patients are not able to undergo the same therapy due to loss of skin elasticity which could complicate surgeries. Age is also a factor for treatments such as chemotherapy; studies have shown chemotherpary can have a significant impact on physical functioning in older patients specifically.
Technology’s role in transforming cancer care
We are at a point in time where personalizing care has become increasingly feasible, not only in cancer but across the care continuum. This rapid adoption has been made possible in large part by technology.
One example of this is Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy). The therapy taps into innovative technology using alpha radiation-emitting sources that are implanted directly into the tumor. These sources then release high-energy alpha particles that target cancer cells while sparing surrounding healthy tissue. In this case, the treatment is a swift outpatient procedure, sparing patients the need for hospitalization. The convenience of an outpatient approach not only reduces the physical implications but also the logistical, financial, and emotional strain on patients and their families. Beyond its minimally invasive approach, the technology ensures effective outcomes with proven cancer kill rates.
These advantages significantly support the overall well-being of patients, addressing both physical and mental needs, and in turn, support quality of care without sacrificing quality of treatment.
Comfort to cure does not mean compromised care
This year’s theme at ASCO “From Comfort to Cure,” underscores the widely accepted movement prioritizing quality of life alongside treatment efficacy. The discussions and advancements highlighted at ASCO challenge providers to reevaluate traditional approaches and embrace personalized solutions that enhance patient outcomes without compromising their well-being.
As we look forward, the integration of patient-centered care models and innovative technology will be significant in advancing the field of oncology. The commitment to balancing cure with comfort prioritizes the dignity, well-being, and preferences of the patient throughout their treatment journey. In conclusion, the dialogue at ASCO 2024 has reinforced the commitment to “First, Do No Harm,” allowing providers to move closer to realizing a future where comfort and cure go hand in hand.
About Dr. Robert Den
Dr. Robert Den is the chief medical officer at Alpha Tau Medical, where he leads clinical research functions. He also is an associate professor of radiation oncology, cancer biology, and urology at Thomas Jefferson University.
